WINCHESTER, Mass., Jan. 26, 2016 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com) is thrilled to announce that Werner Meier is the newest member of its Scientific Advisory Board, which comprises pioneers and thought leaders in the mathematical modeling, biological engineering, biotechnology, and medical fields. Werner joins key opinion leaders Douglas Lauffenburger, PhD, Dr. Joseph Loscalzo, MD, PhD, Bruce Tidor, PhD, and Michael Yaffe, MD, PhD.
"I am delighted to join the Scientific Advisory Board of Applied BioMath and be part of such a distinguished group of thought leaders. In addition, I very much look forward to working with the talented group of Applied BioMath scientists and devise strategies to build models that reduce drug development risk for Appled BioMath clients and partners."
- Werner Meier, former Vice President of Biologics Drug Discovery, Biogen Inc.
During a tenure of over thirty years at Biogen, Werner Meier held various scientific positions with strategic and high-impact responsibilities. Werner was Vice President of Biologics Drug Discovery, responsible for the discovery and development readiness of all therapeutic protein candidates in Research. For over two decades, he guided the discovery, expression, characterization and development transition of more than two dozen novel therapeutic protein candidates including antibodies, receptor-Ig fusion proteins and bispecific antibodies. Werner also served as the Program Executive for two development programs aimed at treating immunologic and neurological diseases and successfully guided these programs through preclinical development and manufacturing into early phase clinical studies.
"Applied BioMath is a leader in the Systems Pharmacology field. Our scientists have worked in industry and we understand the drug discovery process. Customers often site that our industry experience is one thing they value most about working with us. In addition to his world class biologics expertise, Werner brings over 30 years of industry experience. We look forward to leveraging his decades of industry experience as we solidify the role of systems pharmacology in drug invention."
- Dr. Joshua Apgar, PhD, Co-Founder and CSO, Applied BioMath
About Applied BioMath
Applied BioMath (www.appliedbiomath.com) helps biotech and pharmaceutical companies reduce late stage attrition and accelerate best-in-class (BIC) drugs using quantitative methodologies. Leveraging biology, high performance computing (HPC), proprietary technology and experience in pharma, Applied BioMath delivers biological insights proven to shorten project timelines, lower costs, and develop BIC drugs. Services include knowledge gap analysis, experiment prioritization and design, BIC drug property and toxicity predictions, indication and patient selection, and optimal clinical trial design and analysis.
Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.
SOURCE Applied BioMath